DoW Vision, Translational Research Award | HT942526VRPTRA

Opportunity Information: Apply for HT942526VRPTRA

The FY26 Vision Research Program Translational Research Award (TRA) is a Department of the Army (USAMRAA) grant opportunity under the Congressionally Directed Medical Research Programs that focuses on moving vision-related discoveries out of the early research stage and into something that is genuinely ready to be tested in people. The intent is translational: taking a promising finding and turning it into a practical product or deliverable, such as a new drug, a medical device, or a clinical practice guideline, with enough supporting evidence that a definitive clinical trial could begin during the award period or be ready to launch by the time the project ends. In other words, the program is looking for proposals that can credibly bridge the gap between discovery and real-world clinical testing, rather than exploratory work that is still trying to prove a basic concept.

The award can support several types of activities as long as they serve that translation goal. Applicants can propose preclinical development work, clinical research that advances readiness for trials, or even a pilot clinical trial designed to de-risk and inform a later, larger study. What it will not support is a full-scale clinical trial, so projects need to be sized and designed accordingly (for example, focusing on feasibility, dosing, device performance, initial safety signals, workflow validation, or other key steps that enable a later pivotal trial). Another central requirement is that the proposed research must fit within at least one of the FY26 VRP Focus Areas, meaning it needs to align with the program priorities for that year rather than being a general vision science proposal.

Several features of the announcement shape how teams should build their applications. If the project involves developing a drug or a device, the research team is expected to include regulatory approval expertise, reflecting an emphasis on practical advancement toward FDA or other relevant regulatory pathways. The opportunity also offers a Partnering Principal Investigator Option, which allows two PIs to lead together as an Initiating PI and a Partnering PI, supporting collaboration across disciplines or institutions when that is necessary to reach a translational endpoint. Applications will be evaluated through scored peer review criteria that cover the strength of the research idea and rationale, the research strategy and feasibility, the likely impact, the qualifications of the personnel, and a post-award transition plan that explains how the work will move forward after the grant (for example, into a definitive clinical trial, a regulatory submission, commercialization, or adoption into clinical guidance). After peer review scoring, there is also a programmatic review that looks at whether the application fits the intent of the TRA, how it complements the overall VRP portfolio, its relative impact, and its relevance to military health needs, which is a key framing element for Department of Defense medical research funding.

From an administrative standpoint, this is a discretionary grant (Funding Opportunity Number HT942526VRPTRA) in the science and technology/research and development category (CFDA 12.420). Eligibility is listed as unrestricted, which typically means the program is open to a broad range of applicant organizations rather than being limited to a narrow set of institution types. The opportunity is run by the Department of the Army, USAMRAA. The posted original closing date is November 12, 2026, and the listing indicates an expectation of one award, while the award ceiling is not specified in the provided source. One additional point worth noting is that the VRP may share FY26 TRA applications and their reviews with the National Eye Institute (NEI), which creates a potential secondary path for funding consideration outside the DoD program, depending on NEI interest and priorities.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoW Vision, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2026-05-05.
• Applicants must submit their applications by 2026-11-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942526VRPTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: